PURPOSE: Hepatic resection is established as a safe procedure for colorectal, neuroendocrine, and sarcoma liver metastases. The present study evaluates whether liver resection is an option for patients with non-colorectal, non-neuroendocrine, and non-sarcoma metastases of the liver. METHODS: According to data from our prospective clinical tumor registry, we reviewed the medical records of 44 consecutive patients with non-colorectal, non-neuroendocrine, and non-sarcoma liver metastases, who underwent hepatic resection from January 2000 to December 2008. Univariate Kaplan-Meier analysis and a stepwise multivariable Cox regression model were applied. RESULTS: Following hepatic resection, mean overall survival was 21 months, and 5-year survival was 20%. Following hepatic resection, gender, histology, and chemotherapy were of prognostic value in our patient cohort in univariate analysis (p < 0.05). Multivariate survival analysis confirmed chemotherapy (p = 0.002) as an independent prognostic variable. Following initial resection of the primary tumor, synchrone occurrence of metastases, histology, localization of primary, perioperative complications, interval between initial resection of the primary tumor and resection of the metastases, and metastases in follow-up after hepatic resection were of prognostic value in univariate analysis (p < 0.05). Histology (p = 0.017) and interval between resection of the primary and resection of the metastases (p = 0.030) were confirmed as independent prognostic variables in multivariate survival analysis. CONCLUSIONS: Hepatic resection seems to be a safe and promising additive for a selective group of patients with non-colorectal, non-neuroendocrine, and non-sarcoma metastases of the liver.
PURPOSE: Hepatic resection is established as a safe procedure for colorectal, neuroendocrine, and sarcoma liver metastases. The present study evaluates whether liver resection is an option for patients with non-colorectal, non-neuroendocrine, and non-sarcoma metastases of the liver. METHODS: According to data from our prospective clinical tumor registry, we reviewed the medical records of 44 consecutive patients with non-colorectal, non-neuroendocrine, and non-sarcoma liver metastases, who underwent hepatic resection from January 2000 to December 2008. Univariate Kaplan-Meier analysis and a stepwise multivariable Cox regression model were applied. RESULTS: Following hepatic resection, mean overall survival was 21 months, and 5-year survival was 20%. Following hepatic resection, gender, histology, and chemotherapy were of prognostic value in our patient cohort in univariate analysis (p < 0.05). Multivariate survival analysis confirmed chemotherapy (p = 0.002) as an independent prognostic variable. Following initial resection of the primary tumor, synchrone occurrence of metastases, histology, localization of primary, perioperative complications, interval between initial resection of the primary tumor and resection of the metastases, and metastases in follow-up after hepatic resection were of prognostic value in univariate analysis (p < 0.05). Histology (p = 0.017) and interval between resection of the primary and resection of the metastases (p = 0.030) were confirmed as independent prognostic variables in multivariate survival analysis. CONCLUSIONS: Hepatic resection seems to be a safe and promising additive for a selective group of patients with non-colorectal, non-neuroendocrine, and non-sarcoma metastases of the liver.
Authors: Jürgen Weitz; Leslie H Blumgart; Yuman Fong; William R Jarnagin; Michael D'Angelica; Lawrence E Harrison; Ronald P DeMatteo Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: Süleyman Yedibela; Jonas Gohl; Valentina Graz; Mona Kathrin Pfaffenberger; Susanne Merkel; Werner Hohenberger; Thomas Meyer Journal: Ann Surg Oncol Date: 2005-08-18 Impact factor: 5.344
Authors: Srinevas K Reddy; Andrew S Barbas; Carlos E Marroquin; Michael A Morse; Paul C Kuo; Bryan M Clary Journal: J Am Coll Surg Date: 2007-03 Impact factor: 6.113
Authors: Steven A Earle; Eduardo A Perez; Juan C Gutierrez; Danny Sleeman; Alan S Livingstone; Dido Franceschi; Joe U Levi; Craig Robbins; Leonidas G Koniaris Journal: J Am Coll Surg Date: 2006-08-23 Impact factor: 6.113
Authors: Günter Fürst; Jan Schulte am Esch; Ludger W Poll; Stefan B Hosch; L Benjamin Fritz; Michael Klein; Erhard Godehardt; Andreas Krieg; Britta Wecker; Volker Stoldt; Marcus Stockschläder; Claus F Eisenberger; Ulrich Mödder; Wolfram T Knoefel Journal: Radiology Date: 2007-02-20 Impact factor: 11.105
Authors: Anne M Covey; Karen T Brown; William R Jarnagin; Lynn A Brody; Lawrence Schwartz; Scott Tuorto; Constantinos T Sofocleous; Michael D'Angelica; George I Getrajdman; Ronald DeMatteo; Nancy E Kemeny; Yuman Fong Journal: Ann Surg Date: 2008-03 Impact factor: 12.969
Authors: Dayna P Y Sim; Brian K P Goh; Ser-Yee Lee; Chung-Yip Chan; Iain B H Tan; Peng-Chung Cheow; Premaraj Jeyaraj; Pierce K H Chow; London L P J Ooi; Alexander Y F Chung Journal: World J Surg Date: 2018-04 Impact factor: 3.352
Authors: Ravi Marudanayagam; Bynvant Sandhu; M Thamara P R Perera; Phillipe Taniere; Chris Coldham; Simon Bramhall; David Mayer; John Buckels; Darius Mirza Journal: HPB (Oxford) Date: 2011-03-02 Impact factor: 3.647
Authors: Martina Nowak-Machen; Moritz Schmelzle; Dusan Hanidziar; Wolfgang Junger; Mark Exley; Leo Otterbein; Yan Wu; Eva Csizmadia; Glen Doherty; Michail Sitkovsky; Simon C Robson Journal: Am J Respir Cell Mol Biol Date: 2013-05 Impact factor: 6.914
Authors: Martina Nowak-Machen; Martin Lange; Mark Exley; Sherry Wu; Anny Usheva; Simon C Robson Journal: Purinergic Signal Date: 2015-08-26 Impact factor: 3.765
Authors: Hans Michael Hau; Florian Thalmann; Christoph Lübbert; Mehmet Haluk Morgul; Moritz Schmelzle; Georgi Atanasov; Christian Benzing; Undine Lange; Rudolf Ascherl; Roman Ganzer; Dirk Uhlmann; Hans-Michael Tautenhahn; Georg Wiltberger; Michael Bartels Journal: BMC Surg Date: 2016-07-22 Impact factor: 2.102